Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ZG-005 by Suzhou Zelgen Biopharmaceutical for Neuroendocrine Carcinoma: Likelihood of Approval
ZG-005 is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData,...
ZG-005 by Suzhou Zelgen Biopharmaceutical for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
ZG-005 is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...
ZG-005 by Suzhou Zelgen Biopharmaceutical for Hepatocellular Carcinoma: Likelihood of Approval
ZG-005 is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...